protect
viral
diseas
import
com
ponent
prevent
medicin
health
care
program
captiv
carnivor
carnivor
su
ceptibl
varieti
viral
infect
signifi
cant
also
occur
domest
cat
dog
reason
vaccin
program
wild
carnivor
often
model
recommend
domest
counterpart
goal
chapter
assist
zoo
veterinarian
develop
vaccin
program
meet
need
individu
anim
collect
institut
although
carnivor
vaccina
tion
program
bound
similar
among
institu
tion
need
ident
effect
factor
consid
develop
program
includ
follow
risk
exposur
includ
like
hood
exposur
base
environment
factor
geograph
locat
sever
diseas
expos
may
vari
age
speci
gender
reproduct
statu
potenti
advers
reac
tion
one
vaccin
avail
resourc
eg
time
financ
labor
vaccin
alon
reli
prevent
diseas
adjunct
compon
control
infecti
diseas
reduc
ing
exposur
agent
anim
environ
ment
quarantin
practic
clean
disinfect
protocol
pest
predat
control
program
well
minim
factor
stress
overcrowd
inadequ
nutrit
diminish
resist
diseas
use
taxonom
classif
present
wilson
reeder
order
carnivora
divid
two
subord
feliformia
caniformia
tabl
know
speci
catlik
doglik
may
help
predict
diseas
suscept
publish
data
lack
commerci
vaccin
develop
use
domest
speci
use
carnivor
constitut
extralabel
use
although
modifi
live
kill
viru
vaccin
domi
nate
market
thirdgener
product
complement
case
replac
new
technolog
posit
impact
current
practic
improv
safeti
efficaci
vaccin
use
nondomest
carnivor
guidelin
global
applic
vac
cinat
cat
dog
compil
vaccin
guidelin
group
vgg
world
small
anim
veterinari
associ
guidelin
base
provid
american
anim
hospit
associ
aaha
canin
vaccin
task
forc
felin
vaccin
advisori
panel
american
associ
felin
practition
guidelin
also
consist
european
advisori
board
cat
diseas
south
african
veterinari
council
inform
chapter
con
dens
version
taken
directli
guidelin
special
attent
might
appli
nondomest
carnivor
inform
subject
chang
light
develop
research
technol
ogi
experi
vgg
recommend
cat
dog
benefit
vaccin
vaccin
protect
individu
provid
optimum
herd
immun
reduc
number
suscept
anim
region
popula
tion
decreas
diseas
preval
specif
recom
mendat
base
concept
core
vaccin
core
vaccin
everi
cat
dog
regardless
circumst
receiv
core
vaccin
protect
anim
sever
lifethreaten
diseas
global
distribut
vaccin
program
includ
vaccin
anim
truli
need
vaccin
potenti
caus
advers
reaction
core
vaccin
felid
protect
felin
parvoviru
panleukopenia
fpv
felin
caliciviru
fcv
felin
herpesviru
fhv
rabi
viru
includ
core
group
area
world
rabi
endem
except
australia
great
britain
japan
island
rabi
present
worldwid
parenter
kill
fpv
vaccin
usual
prefer
vaccineassoci
diseas
occur
use
modifi
live
ml
product
although
document
ml
fpv
vaccin
immun
take
week
develop
first
dose
kill
vaccin
least
week
second
dose
contrast
ml
fpv
provid
longlast
immun
approxi
mate
day
cat
older
week
product
contain
ml
fpv
also
contain
ml
fcv
ml
fhv
similarli
product
contain
kill
fpv
contain
kill
fcv
fhv
kill
vaccin
use
pregnant
anim
use
diseasefre
collect
use
ml
product
includ
intranas
fpvfcvfhv
vaccin
introduc
caliciviru
herpesviru
collect
previous
free
condit
recommend
nondomest
carnivor
protect
afford
fcv
fhv
vaccin
either
kill
ml
provid
efficaci
immun
seen
fpv
vaccin
vaccin
prevent
infect
fcv
fhv
system
local
cellmedi
humor
immun
play
import
role
prevent
reduc
ing
sever
diseas
although
fcv
vaccin
design
produc
crossprotect
immu
niti
sever
clinic
diseas
multipl
strain
fcv
therefor
possibl
infect
mild
diseas
occur
vaccin
anim
virul
system
caliciviru
vscv
recent
describ
vaccin
current
vaccin
protect
felid
field
infect
pro
tection
shown
experiment
fhv
vaccin
ml
kill
protect
infect
virul
strain
herpesviru
virul
strain
herpesviru
becom
latent
may
reactiv
period
sever
stress
life
felid
reactiv
viru
may
caus
clinic
sign
vaccin
anim
viru
shed
suscept
anim
caus
diseas
seen
frequent
captiv
cheetah
vaccin
preg
nanci
help
protect
kitten
prolong
matern
deriv
antibodi
mda
cat
may
becom
infect
canin
parvoviru
certain
strain
may
caus
sign
panleukopenia
cat
convent
fpv
vaccin
shown
protect
canin
parvovirus
report
cheetah
vaccin
kill
fpv
vaccin
develop
canin
parvoviru
infect
gastrointesti
nal
diseas
core
vaccin
canid
protect
canin
distemp
viru
cdv
canin
adenoviru
cav
canin
parvoviru
cpv
rabi
viru
includ
core
group
area
world
rabi
endem
area
facil
cdv
endem
domest
wild
suscept
speci
ml
vaccin
use
risk
introduc
viru
host
popul
unaccept
abl
suscept
wild
carnivor
speci
shed
viru
follow
ml
cdv
vaccin
administr
may
develop
diseas
report
red
panda
blackfoot
ferret
european
mink
gray
fox
kinkaj
south
american
bush
dog
mane
wolf
ml
cdv
product
avail
contain
virul
strain
use
domest
dog
poxviru
recom
binant
canin
distemp
vaccin
rcdv
avail
mani
countri
consid
vaccin
choic
nondomest
carnivor
protect
vaccin
induc
diseas
natur
infect
recombi
nant
vaccin
ad
advantag
safe
younger
anim
effect
immun
carnivor
mda
absenc
mda
rcdv
vaccin
provid
immun
immedi
vaccina
tion
rcdv
vaccin
current
avail
monoval
product
combin
ml
cpv
ml
cav
ml
cpv
ml
cav
canin
parainflu
enza
viru
cpi
cpi
consid
option
vaccin
see
later
four
genotyp
canin
parvoviru
recogn
cpvcand
genotyp
antigen
compar
mean
vaccin
one
genotyp
provid
protect
immun
geno
type
cpv
hypothes
natur
genet
mutat
fpv
first
emerg
dog
cpv
strain
replic
canin
felin
cell
fpv
shown
replic
effici
felin
cell
kill
cpv
vaccin
avail
less
effect
ml
vaccin
addit
often
combin
ml
cdv
vaccin
although
kill
vaccin
prefer
use
wild
nondomest
speci
kill
product
may
best
choic
part
polyval
vaccin
contain
ml
cdv
reason
note
earlier
canid
suscept
sever
diseas
caus
cpv
infect
first
year
life
institu
tion
decid
whether
could
effect
isol
pup
prevent
introduct
diseas
whether
benefit
use
ml
cpv
product
outweigh
risk
ml
cpv
vaccin
result
shed
viru
viru
could
potenti
revert
virul
well
infect
individu
speci
environ
viru
remain
infecti
year
longer
similar
ml
fpv
vaccin
ml
cpv
vaccin
provid
immun
day
vaccin
cpv
first
appear
fpv
vaccin
use
provid
protect
specif
vaccin
manufac
ture
known
whether
kill
fpv
monova
lent
vaccin
protect
cpv
nondomest
carnivor
recent
studi
suggest
may
offer
protect
altern
one
could
con
sider
revaccin
canid
posit
antibodi
titer
cpv
postvaccin
use
ml
product
lifelong
immun
result
experiment
canin
dna
vaccin
develop
hold
promis
futur
contrast
ml
cpv
vaccin
ml
cav
vaccin
viru
shown
revert
virul
back
passag
studi
ml
contain
vaccin
commonli
avail
product
prevent
infecti
canin
hepat
ich
caus
reduc
sign
respiratori
diseas
caus
also
caus
advers
reaction
commonli
seen
vaccin
known
allerg
uveiti
blue
eye
mda
significantli
interfer
efficaci
core
vaccin
current
avail
except
rcdv
vaccin
level
mda
vari
among
litter
young
carnivor
receiv
three
dose
vaccin
repeat
inject
first
year
life
constitut
booster
rather
attempt
induc
primari
immun
respons
gener
passiv
immun
wane
week
level
allow
activ
immun
age
begin
vaccin
seri
vari
vaccin
typic
begun
week
age
readminist
interv
anim
week
age
week
usual
prefer
ensur
wane
matern
anti
bodi
complet
start
immun
earli
week
may
appropri
situat
high
risk
eg
fhv
cheetah
question
mda
statu
situat
one
vaccin
administ
done
anim
immunolog
capabl
respondingthat
age
week
older
initi
seri
three
vaccin
anim
receiv
booster
month
initi
seri
booster
refer
primari
vaccin
cours
booster
month
also
ensur
immun
carnivor
adequ
respond
first
seri
vaccin
core
vaccin
given
frequent
everi
year
thereaft
report
literatur
suggest
durat
immun
least
year
kill
product
use
notabl
except
annual
booster
requir
associ
zoo
aquaria
eaza
european
endang
speci
programm
eep
would
also
valuabl
resourc
combin
product
cdv
current
often
includ
cpi
viru
new
coreonli
product
develop
includ
cpi
howev
effect
rout
vac
cinat
cpi
intranas
local
immun
import
system
immun
canin
influenza
viru
civ
antigen
unrel
viru
dog
relat
equin
influenza
viru
first
infect
greyhound
florida
viru
caus
signific
respiratori
diseas
initi
outbreak
present
known
whether
viru
import
caus
canin
respira
tori
diseas
emerg
diseas
dog
often
acut
mild
moder
clinic
sign
dog
mortal
low
readili
spread
dog
area
thu
remain
rel
confin
affect
group
mani
que
tion
role
influenza
viru
virus
cpi
bacteria
b
bronchiseptica
variou
mycoplasma
factor
caus
canin
respiratori
diseas
complex
remain
unansw
b
bronchiseptica
option
vaccin
nondomest
carnivor
like
indic
zoolog
cal
collect
organ
howev
transmit
ted
canid
felid
use
import
realiz
vaccin
need
given
everi
month
consid
low
efficaci
advers
event
rate
minim
risk
leptospirosi
mani
region
unit
state
practition
use
current
product
howev
anim
highrisk
environ
leptospirosi
product
use
contain
four
serovar
signific
cross
protect
anim
vaccin
start
ing
earlier
week
age
revaccin
week
revaccin
month
age
revaccin
year
age
may
need
revaccin
often
everi
month
optim
protect
use
program
anim
develop
clinic
diseas
leptospira
may
get
infect
shed
organ
urin
vaccin
classifi
recommend
insuffici
scientif
evid
justifi
use
current
includ
felin
infec
tiou
periton
vaccin
felin
giardia
vaccin
new
fcv
vaccin
kill
adjuv
vaccin
design
aid
prevent
vscv
field
long
enough
know
whether
recombin
viru
nonadjuv
canarypoxvector
rabi
vaccin
label
use
domest
cat
reason
kill
rabi
vaccin
often
chosen
despit
concern
use
adjuv
primari
rabi
vac
cinat
occur
week
age
revaccin
year
later
annual
triennial
vaccina
tion
follow
depend
type
vaccin
use
applic
legal
requir
push
toward
market
vaccin
extend
durat
immun
doi
reduc
unnecessari
administr
vaccin
therebi
improv
vaccin
safeti
noncor
vaccin
requir
anim
whose
geograph
locat
local
envi
ronment
lifestyl
place
risk
contract
specif
infect
assess
risk
benefit
prior
choos
use
noncor
vaccin
assess
includ
evalu
risk
infect
sever
diseas
efficaci
product
avail
although
felin
leukemia
viru
felv
vaccin
recommend
noncor
vaccin
domest
cat
test
neg
viru
vaccin
recommend
nondomest
felid
nondom
tic
felid
test
felv
felin
immuno
defici
viru
fiv
neg
posit
anim
manag
separ
lieu
vaccin
antibodi
produc
follow
fiv
vaccin
interfer
antibodybas
fiv
diagnost
test
pass
queen
kitten
colostrum
addi
tional
noncor
vaccin
includ
chlamydophila
feli
vaccin
bordetella
bronchiseptica
vaccin
although
chlamydophila
bordetella
contribut
felin
respiratori
diseas
complex
valu
need
vaccin
control
complex
diseas
question
import
therefor
use
que
tionabl
import
cat
also
recogn
two
vaccin
associ
varieti
advers
reaction
small
percentag
anim
rcdv
vaccin
would
noncor
vaccin
could
valuabl
use
nondomest
felid
eg
genu
panthera
lynx
suscept
catlik
carnivor
speciesspecif
recommenda
tion
reader
encourag
refer
guidelin
provid
associ
zoo
aquarium
aza
taxon
advisori
group
tag
speci
surviv
plan
ssp
veterinari
advisor
similarli
european
valu
short
time
period
antibodi
persist
lack
correl
serum
antibodi
protect
eg
canin
parainflu
enza
fhv
absenc
detect
serum
anti
bodi
level
vaccin
felid
necessarili
indic
cat
suscept
diseas
cell
mediat
immun
play
import
role
protec
tion
howev
fhv
seroconvers
correl
protect
virul
fhv
import
consid
ation
perform
antibodi
test
cost
time
obtain
result
vgg
recommend
follow
inform
record
anim
medic
record
veterinarian
encourag
report
possibl
advers
event
manufactur
andor
regulatori
author
expand
knowledg
base
drive
develop
improv
vaccin
safeti
advers
event
defin
side
effect
unintend
cons
quenc
includ
lack
protect
associ
vaccin
whether
event
directli
attribut
vaccin
local
inject
site
reac
tion
follow
vaccin
includ
pain
pruriti
swell
alopecia
abscess
format
granuloma
mation
neoplasia
system
reaction
event
involv
entir
bodi
defin
locat
region
inject
site
angio
edema
anaphylaxi
vomit
diarrhea
respiratori
di
tress
fever
lethargi
neurolog
behavior
chang
immunemedi
diseas
inject
adjuv
vaccin
associ
local
inflammatori
reaction
inject
site
degre
inflamma
tion
vari
among
product
potenti
role
local
inflammatori
reaction
genesi
vaccin
associ
sarcoma
remain
controversi
vaccin
potenti
caus
advers
reaction
reaction
depend
product
also
individu
anim
often
genet
pre
disposit
lead
advers
immun
reaction
cancer
current
vaccin
recommend
stress
veterinarian
administ
vaccin
valu
prevent
reduc
develop
extrem
rare
diseas
vscv
first
recogn
cat
approxim
year
ago
result
one
respiratori
strain
caliciviru
mutat
variant
caus
except
virul
acut
system
diseas
acut
diseas
caus
higher
mortal
use
vaccin
recommend
time
geograph
distribut
lyme
diseas
suggest
vaccin
would
benefit
certain
us
region
thu
widespread
use
product
neither
necessari
desir
tick
control
prevent
antibiot
treatment
must
use
highrisk
area
vaccin
guidelin
aaha
neither
giardia
coronaviru
vaccin
recom
mend
unless
proven
benefici
specif
anim
also
new
vaccin
snake
bite
crotalu
spp
periodont
diseas
porphyromona
spp
scientif
research
pre
sent
support
use
antibodi
test
use
monitor
immun
core
vaccin
fpv
cdv
cav
cpv
neg
test
result
indic
anim
littl
antibodi
revaccin
recom
mend
juvenil
carnivor
complet
vaccin
seri
week
age
anim
test
posit
antibodi
serum
sampl
collect
week
last
vac
cinat
seroneg
anim
revaccin
retest
may
interfer
mda
unlik
week
age
vaccin
use
poorli
immunogen
anim
test
neg
consid
nonrespond
possibl
incap
develop
protect
immu
niti
immun
system
fail
recogn
anti
genic
determin
specif
vaccin
vaccin
carnivor
persist
serum
antibodi
core
vaccin
antigen
mani
year
core
vaccin
excel
correla
tion
presenc
antibodi
protect
immun
long
doi
product
antibodi
absent
anim
revac
cinat
unless
medic
logist
basi
antibodi
determin
vaccin
com
ponent
list
earlier
limit
anim
truli
need
addit
vaccin
given
requir
vaccin
potenti
caus
advers
reaction
